Novo Nordisk halts two more ziltivekimab cardiovascular trials
Novo Nordisk said it has halted two additional trials of its experimental cardiovascular drug ziltivekimab, further denting efforts to diversify beyond its obesity and diabetes franchise.
Novo Nordisk OMXCOP:NOVO_B said on Monday it had halted two more trials of its experimental cardiovascular drug ziltivekimab, deepening a setback for the Danish drugmaker’s push to broaden beyond its blockbuster obesity and diabetes business. In July, Novo said ziltivekimab fa…